

BACKGROUND PAPER

Corporate Executive Board

Gabriel Baertschi Chairman of the Corporate Executive Board, Chief Executive Officer



Gabriel Baertschi joined the Grünenthal Group in October 2016 taking over the position as Chairman of the Corporate Executive Board and Chief Executive Officer.

Gabriel Baertschi brings more than 20 years of international experience in the pharmaceutical industry; most of the time he worked for AstraZeneca. Before taking over the position at Grünenthal, he was country president in Japan (2013 – 2016).

Previously, he served as country president for Germany (2010 – 2012), Thailand (2009 – 2010) and Vietnam

(2006 - 2009). Prior to his appointment to senior management Gabriel Baertschi held various strategic functions in international sales and marketing.

After studying biology at the University of Neuchâtel he started his career as a sales representative in the medical sector for Servier in Switzerland.

Gabriel Baertschi was born in 1974 in Bern/Switzerland.

Sascha Becker Member of the Corporate Executive Board, Chief Financial Officer



In March 2015, Sascha Becker joined the Grünenthal Group as Chief Financial Officer and a member of the Corporate Executive Board. In his position, he takes responsibility for the areas Finance and IT.

Previously, Sascha Becker worked for Merck KGaA for more than twelve years, holding various positions in the area of finance. When he joined the company in 2003, he built the capital markets unit in order to broaden the financial sources for the Group.

Contact: Štěpán Kráčala, Head Global Communications

Tel.: +49 241 569-1335, Fax: +49 241 569-51335 stepan.kracala@grunenthal.com

Grünenthal GmbH, 52099 Aachen, Germany, www.grunenthal.com



BACKGROUND PAPER

Corporate Executive Board

From 2006 to 2009 he led Investor Relations before moving to the UK as Chief Financial Officer. In addition to the core finance functions, he oversaw Business Development, Market Insight, IT, Procurement, and Legal & Compliance.

From 2012, Sascha Becker was responsible for the global biopharmaceutical division Merck Serono as Chief Financial Officer. As a member of the Pharma Executive Committee, he was heavily involved in the implementation of the efficiency program and strategy definition of the division.

Prior to joining Merck, Sascha Becker had worked at the Deutsche Bank AG in corporate banking and as a debt capital market specialist. He was awarded a bachelor's degree in applied science from the University of Applied Sciences in Aachen and a Master of Business Administration from Ashridge Business School, UK. Sascha Becker was born in 1970 in Aachen/Germany.

Mark Fladrich Member of the Corporate Executive Board, Chief Commercial Officer



Mark Fladrich joined the Grünenthal Group in September 2017 as Chief Commercial Officer and member of the Corporate Executive Board.

He started his career in the pharmaceutical industry in 1988 and has been working on the commercial side of the business with AstraZeneca for the last 20 years.

Since 2011 Mark Fladrich has worked in major commercial Profit & Loss roles, including the position of Country President for Australia and New Zealand and the position of Area Vice President Southern and Western Europe.

In 2010, he was appointed Vice President Global Commercial Excellence with responsibility for pricing, market access, business insight, medical affairs, communications, sales, marketing, new channels capability development, portfolio management and forecasting.

In 2008, Mark Fladrich was promoted to Vice President Global Brands at the UK Headquarters where he assumed responsibility for the strategic marketing of the company's Phase III projects as well as the marketed products across all therapeutic areas (oncology, diabetes, respiratory, CNS).

Contact: Štěpán Kráčala, Head Global Communications

Tel.: +49 241 569-1335, Fax: +49 241 569-51335 stepan.kracala@grunenthal.com

Grünenthal GmbH, 52099 Aachen, Germany, www.grunenthal.com



BACKGROUND PAPER

Corporate Executive Board

In 2005 he was appointed to Marketing Company President Germany. Prior to that, he was Vice President International Sales & Marketing in Belgium. From 1999 Mark Fladrich worked as Director Sales and Marketing in Australia.

Before joining AstraZeneca Pharmaceuticals in 1997, he held diverse positions in other pharmaceutical companies. He completed a Bachelor of Pharmacy at the South Australian Institute of Technology in Adelaide, Australia and a Master of Business Administration at Macquarie University in Sydney, Australia. Mark Fladrich was born in 1959 in South Australia.

Dr. Philip Just Larsen Member of the Corporate Executive Board, Chief Scientific Officer



In July 2018 Dr. Philip Just Larsen was appointed Chief Scientific Officer and Member of the Corporate Executive Board, assuming leadership of Grünenthal's research & development organization.

Previously, Philip gained a wealth of experience in the pharmaceutical industry, working for Eli Lilly, AstraZeneca and Sanofi in Europe and the US. In January 2016 he took over the role of Chief Scientific Officer at Sanofi's German Hub in Frankfurt. At the same time, he remained Global Head of Diabetes Research and Translational Science, a

position he served since August 2012.

Philip started his career at Novo Nordisk as Department Head Neuropharmacology followed by various management positions with increasing responsibility. He studied at the University of Copenhagen, is a Medical Doctor trained in internal medicine and neurology, and has been awarded a PhD in Neuroscience/Endocrinology.

The portrait photos can be downloaded from the media section on our website.

Contact: Štěpán Kráčala, Head Global Communications

Tel.: +49 241 569-1335, Fax: +49 241 569-51335 stepan.kracala@grunenthal.com

Grünenthal GmbH, 52099 Aachen, Germany, www.grunenthal.com